ArticleScientific reports2017
Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition.
Joyoti Dey et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
55 papers cite it
this papertrialcites it